566 related articles for article (PubMed ID: 16891172)
1. Repair of topoisomerase I-mediated DNA damage.
Pommier Y; Barcelo JM; Rao VA; Sordet O; Jobson AG; Thibaut L; Miao ZH; Seiler JA; Zhang H; Marchand C; Agama K; Nitiss JL; Redon C
Prog Nucleic Acid Res Mol Biol; 2006; 81():179-229. PubMed ID: 16891172
[TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerases as targets for anticancer drugs.
Topcu Z
J Clin Pharm Ther; 2001 Dec; 26(6):405-16. PubMed ID: 11722677
[TBL] [Abstract][Full Text] [Related]
3. Symposium: downstream from topoisomerase-DNA lesions: life-or-death consequences for the cell.
Kohn KW; Andoh T
Cell Biochem Biophys; 2000; 33(2):171-3. PubMed ID: 11325036
[No Abstract] [Full Text] [Related]
4. Topoisomerase I-mediated DNA damage.
Pourquier P; Pommier Y
Adv Cancer Res; 2001; 80():189-216. PubMed ID: 11034544
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced stabilization of covalent DNA topoisomerase I-DNA intermediates. DNA cleavage assays.
Fiorani P; Hann CL; Benedetti P; Bjornsti MA
Methods Mol Biol; 2001; 95():291-301. PubMed ID: 11089241
[No Abstract] [Full Text] [Related]
6. Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy.
Xu Y; Her C
Biomolecules; 2015 Jul; 5(3):1652-70. PubMed ID: 26287259
[TBL] [Abstract][Full Text] [Related]
7. The dihydropyridine dexniguldipine hydrochloride inhibits cleavage and religation reactions of eukaryotic DNA topoisomerase I.
Straub T; Boesenberg C; Gekeler V; Boege F
Biochemistry; 1997 Sep; 36(35):10777-83. PubMed ID: 9271509
[TBL] [Abstract][Full Text] [Related]
8. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.
Thielmann HW; Popanda O; Gersbach H; Gilberg F
Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865
[TBL] [Abstract][Full Text] [Related]
9. Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage.
Adachi N; So S; Koyama H
J Biol Chem; 2004 Sep; 279(36):37343-8. PubMed ID: 15218034
[TBL] [Abstract][Full Text] [Related]
10. Is DNA topoisomerase involved in the UV excision repair process? New evidence from studies with DNA intercalating and non-intercalating antitumor agents.
Snyder RD
Photochem Photobiol; 1987 Jan; 45(1):105-11. PubMed ID: 3031707
[No Abstract] [Full Text] [Related]
11. Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells.
Murai J; Huang SY; Das BB; Dexheimer TS; Takeda S; Pommier Y
J Biol Chem; 2012 Apr; 287(16):12848-57. PubMed ID: 22375014
[TBL] [Abstract][Full Text] [Related]
12. UnTTrapping the ends: a new player in overcoming protein linked DNA damage.
Bahmed K; Nitiss KC; Nitiss JL
Cell Res; 2010 Feb; 20(2):122-3. PubMed ID: 20118967
[No Abstract] [Full Text] [Related]
13. The response of eukaryotic topoisomerases to DNA damage.
Kingma PS; Osheroff N
Biochim Biophys Acta; 1998 Oct; 1400(1-3):223-32. PubMed ID: 9748592
[TBL] [Abstract][Full Text] [Related]
14. Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions.
Plo I; Liao ZY; Barceló JM; Kohlhagen G; Caldecott KW; Weinfeld M; Pommier Y
DNA Repair (Amst); 2003 Oct; 2(10):1087-100. PubMed ID: 13679147
[TBL] [Abstract][Full Text] [Related]
15. Yeast histone 2A serine 129 is essential for the efficient repair of checkpoint-blind DNA damage.
Redon C; Pilch DR; Rogakou EP; Orr AH; Lowndes NF; Bonner WM
EMBO Rep; 2003 Jul; 4(7):678-84. PubMed ID: 12792653
[TBL] [Abstract][Full Text] [Related]
16. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis.
Li XG; Haluska P; Hsiang YH; Bharti AK; Kufe DW; Liu LF; Rubin EH
Biochem Pharmacol; 1997 Apr; 53(7):1019-27. PubMed ID: 9174116
[TBL] [Abstract][Full Text] [Related]
17. Guanidine-reactive agent phenylglyoxal induces DNA damage and cancer cell death.
Calderón-Montaño JM; Burgos-Morón E; Orta ML; Pastor N; Perez-Guerrero C; Austin CA; Mateos S; López-Lázaro M
Pharmacol Rep; 2012; 64(6):1515-25. PubMed ID: 23406762
[TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I.
Boothman DA; Trask DK; Pardee AB
Cancer Res; 1989 Feb; 49(3):605-12. PubMed ID: 2535961
[TBL] [Abstract][Full Text] [Related]
20. AK37: the first pyridoacridine described capable of stabilizing the topoisomerase I cleavable complex.
Marshall KM; Holden JA; Koller A; Kashman Y; Copp BR; Barrows LR
Anticancer Drugs; 2004 Oct; 15(9):907-13. PubMed ID: 15457132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
